Author: Ravi Shankar

SEATTLE and VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that new data evaluating the efficacy of 52 weeks of cytisinicline treatment for cigarette smoking and e-cigarette cessation will be presented at CHEST 2026, held October 18-21 in Phoenix, Arizona.

CHEST 2026 Presentation Details

• Presentation Title: Efficacy of 52-Week Cytisinicline Treatment for Cigarette Smoking and E-Cigarette Cessation: The Open-Label ORCA-OL Trial
• Session: Top Late-Breaking Abstracts: New Trial Data from Bench to Bronchoscope
• Date/Time: Tuesday, October 20, 2026, 2:09–2:13 p.m. MST
• Presenter: Mark Rubinstein, MD, Chief Medical Officer, Achieve Life Sciences
• Authors: Judith J. Prochaska, PhD, MPH, Stanford University; Neal L. Benowitz, MD, University of California, San Francisco; Dorothy K. Hatsukami, PhD, Masonic Cancer Center, University of Minnesota; Matthew E. Linley-Adams, Achieve Life Sciences; Mark L. Rubinstein, MD, Achieve Life Sciences; Nancy A. Rigotti, MD, Harvard Medical School

The presentation will feature results from ORCA-OL, an open-label study that enrolled 475 adults who previously participated in the ORCA-2, ORCA-3 or ORCA-V1 trials and were actively smoking cigarettes and/or vaping daily. Participants received cytisinicline 3 mg three times daily for 52 weeks with behavioral support. The analysis evaluated abstinence throughout the 52-week treatment period, including biochemically verified four-week sustained abstinence and seven-day point prevalence abstinence.

For more information about the conference, visit https://www.chestnet.org/learning-and-events/events/chest-annual-meeting.

About Cytisinicline
There are approximately 25 million adults in the United States who smoke combustible cigarettes.¹ Tobacco use is currently the leading cause of preventable death, responsible for more than seven million deaths worldwide and nearly half a million deaths in the United States annually.²,³

In addition, there are nearly 18 million adults in the United States who use e-cigarettes, also known as vaping.¹ In 2025, approximately 1.4 million middle and high school students in the United States reported using e-cigarettes.⁴ There are no FDA-approved treatments indicated specifically as an aid to nicotine e-cigarette cessation. FDA has awarded Achieve the Commissioner’s National Priority Voucher for e-cigarette or vaping cessation and granted Breakthrough Therapy designation to address this critical need.

Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine dependence for smoking and e-cigarette cessation by interacting with nicotine receptors in the brain, reducing the severity of nicotine craving symptoms, and reducing the reward and satisfaction associated with nicotine products.

About Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence. Achieve’s New Drug Application (NDA) for cytisinicline for smoking cessation in adults is supported by two successfully completed Phase 3 studies and an open-label long-term safety study. Achieve has also completed a Phase 2 study of cytisinicline in nicotine e-cigarette cessation, conducted an end-of-Phase 2 meeting with the FDA, and has received Breakthrough Therapy designation for the vaping cessation indication.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements regarding the potential benefits of cytisinicline, the potential market for cytisinicline, and the Company’s commercialization plans and readiness. Achieve may not achieve its plans, projections, or other expectations and may not be able to successfully complete its NDA resubmission or obtain regulatory approval for cytisinicline on the anticipated timeline or at all. These statements are based on management’s current expectations and beliefs and are subject to risks, uncertainties, and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including those detailed in Achieve’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Achieve undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

Achieve Contact
Investor Relations
Nicole Jones
ir@achievelifesciences.com
425-686-1510

References
¹Agaku I. Tobacco Product Use among U.S. Adults, 2023–2024, NEJM Evidence, doi: 10.1056/EVIDpha2500339.
²World Health Organization. WHO Report on the Global Tobacco Epidemic, 2025. Geneva: World Health Organization; 2025.
³U.S. Department of Health and Human Services. The Health Consequences of Smoking, 50 Years of Progress. A Report of the Surgeon General. Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
⁴Eunice Park-Lee, Lauren M Dutra, Hannah Cowan, et al. Tobacco Product Use Among Middle and High School Students in the United States: National Youth Tobacco Survey, 2025, Nicotine & Tobacco Research, 2026; ntag116, doi.org/10.1093/ntr/ntag116.

Proposed Acquisition Would Mark ECGI’s Entry into the $5.3 Trillion U.S. Healthcare Industry with an Experienced Operating Team Across Medicare Advantage, Healthcare Services, Insurance Administration and AI-Enabled Health Technology

ORANGE, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) — via IBN — ECGI Holdings, Inc. (OTC: ECGI) (“ECGI” or the “Company”) today announced that it has entered into a non-binding letter of intent to acquire Avanta Group, Inc. and its subsidiaries (collectively, “Avanta”). The proposed transaction represents a pivotal step in ECGI’s strategy to build a diversified healthcare platform spanning a developing Medicare Advantage health plan, healthcare management services, health technology, consumer health and supporting real estate infrastructure.

The proposed acquisition remains subject to due diligence, negotiation and execution of definitive agreements, required corporate and regulatory approvals, and customary closing conditions. Avanta Health Plan, Inc. is in development and will require applicable approvals and licenses, including from the California Department of Managed Health Care and the Centers for Medicare & Medicaid Services, before it may operate or enroll members.

Proposed Transaction Structure

Under the letter of intent, ECGI would acquire Avanta Group, Inc. and its subsidiaries for up to 15,600,000 shares of newly designated Series V Preferred Stock. Twenty percent of the consideration would vest upon execution of a definitive agreement and be issued only at closing. The remaining 80% would vest in four equal tranches upon achievement of recurring revenue milestones of $100 million, $200 million, $300 million and $400 million, with any unvested shares contemplated to vest automatically on the fifth anniversary of closing. Each vested and issued Series V share would be convertible into 1,000 shares of ECGI common stock, subject to the definitive agreements, the Certificate of Designation and applicable law. ECGI would designate the new Series V Preferred Stock, with its additional terms to be disclosed in the definitive transaction documents and applicable public filings.

The parties are proceeding with due diligence and negotiation of definitive transaction documents. There can be no assurance that a definitive agreement will be reached, that regulatory or other approvals will be obtained, or that the proposed acquisition will be completed on the contemplated terms or at all.

“This is a pivotal moment for ECGI,” said Jamie Steigerwald, President of ECGI Holdings. “The Avanta platform is designed to connect the core functions that increasingly shape healthcare performance: insurance, administration, technology, member engagement and the infrastructure required to support delivery. We believe that combination can give ECGI a scalable foundation for growth while keeping the member experience and responsible use of data at the center of the strategy.”

Steigerwald continued, “Healthcare is one of the largest and most consequential sectors of the U.S. economy. Our objective is not simply to participate in that market, but to build an integrated platform capable of using automation and artificial intelligence to improve navigation, identify opportunities for earlier intervention, streamline administrative workflows and support more informed decision-making. We intend to pursue that opportunity with disciplined execution, strong governance and appropriate privacy, cybersecurity, clinical and regulatory controls.”

“We are excited to embark on this venture together with ECGI at such an important stage in Avanta’s development,” said Chi Luong, Chair of the Board of Avanta Group, Inc. “ECGI shares our vision of building a connected healthcare platform that combines insurance, operating expertise and technology to improve how members access and experience care. We believe this transaction can provide the strategic foundation and public-market platform needed to advance that vision, expand our capabilities and create meaningful long-term value for patients, partners and shareholders.”

The $5.3 Trillion United States Healthcare Market

The proposed transaction would position ECGI within a large healthcare market supported by long-term demographic demand. According to the Centers for Medicare & Medicaid Services (CMS), U.S. national health expenditures grew 7.2% to $5.3 trillion in 2024, representing 18.0% of gross domestic product. Medicare spending accounted for approximately $1.12 trillion of that total, while private health insurance spending reached approximately $1.64 trillion. CMS projects that Medicare spending will grow by an average of 7.7% annually from 2025 through 2034, faster than other major sources of healthcare funding.

The Medicare Advantage Market

Medicare Advantage is a substantial part of the broader healthcare market. In February 2026, approximately 35.5 million people were enrolled in Medicare Advantage plans, representing 55% of beneficiaries eligible to enroll. CMS also projected that its final 2026 payment policies would increase payments to Medicare Advantage plans by 5.06%, or more than $25 billion, compared with 2025.

ECGI believes the scale of Medicare Advantage, combined with advances in AI-enabled health technology, presents opportunities to improve member engagement, care navigation, risk identification and administrative efficiency. These remain strategic objectives. Their development and deployment will depend on regulatory requirements, data availability, validation and operational readiness.

The Proposed Avanta Platform

• Avanta Health Plan, Inc.: a developing Medicare Advantage, Commercial, and Individual health-plan insurance entity, subject to all required licenses and approvals.
• Avanta MSO, LLC: a management-services organization intended to support healthcare administration and operations within Avanta’s medical network, directly implementing Avanta Tech and Avanta Health Plan’s innovations at the clinical level.
• Avanta Tech, Inc.: a health-technology business expected to support data, automation and AI-enabled capabilities.
• Avanta Mart, LLC: a consumer-health and wellness channel intended to deepen member and community engagement.
• Avanta Properties City Parkway, LLC: a real-estate entity intended to support healthcare-related infrastructure.

If completed, ECGI expects the transaction to create a unified platform through which technology and data can support multiple operating functions. Potential applications include member-service automation, care-gap identification, provider and network analytics, claims and workflow support, fraud-waste-and-abuse detection, and personalized health navigation. No assurance can be given that any specific capability will be developed, approved, deployed or produce the anticipated results.

About ECGI Holdings

ECGI Holdings, Inc. (OTC: ECGI) is a publicly traded holding company pursuing opportunities to build and scale operating businesses in large, evolving markets.

The Company’s core AI team includes Mr. Lev, who has more than a decade of experience in machine learning, quantitative financial modeling and decentralized systems. Most recently, he led generative-AI platform integration and machine-learning infrastructure at Elation, where he built production-scale large-language-model and telemetry systems connecting enterprise data with operational decision-making. Earlier, he co-founded Skryty, an AI firm that engineered a GPU-accelerated trading engine capable of real-time pattern recognition across NASDAQ market feeds. His prior work at Goldman Sachs and Bloomberg adds deep experience in signal generation, large-scale data engineering and applied financial intelligence. Additional information is available through the Company’s public disclosures.

About Avanta Group

Avanta Group, Inc. is developing a diversified healthcare platform across Medicare Advantage, healthcare management services, health technology, consumer health and supporting real estate. Avanta Health Plan’s contemplated operations remain subject to required licenses and regulatory approvals. Avanta was founded by a team of healthcare operations executives who have a successful track record of building other Medicare Advantage plans and medical clinics. The team understands the needs of diverse ethnic groups related to their health benefits and well-being.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include, among other things, statements regarding the proposed acquisition of Avanta; the negotiation and execution of definitive agreements; the creation and terms of Series V Preferred Stock; the issuance, vesting and conversion of transaction consideration; regulatory and corporate approvals; Avanta Health Plan’s licensing, launch and enrollment; the development and deployment of AI-enabled technologies; anticipated synergies, market opportunities, operating performance and growth. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially. Such risks include the parties’ ability to complete due diligence and agree on definitive terms; financing and capital requirements; dilution; regulatory, licensing and compliance requirements; cybersecurity and data-privacy risks; technology-development and validation risks; competition; reimbursement and policy changes; and other risks described in ECGI’s filings and public disclosures. Readers should not place undue reliance on forward-looking statements. ECGI undertakes no obligation to update such statements except as required by law.

Investor Relations, Media Relations and Corporate Communications
Investor Relations
jamie@ecgiholdings.com

Media Relations
media@nightfoodholdings.com

Corporate Communications
Editor@InvestorBrandNetwork.com
IBN | Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000

Market Data Sources

Centers for Medicare & Medicaid Services, National Health Expenditure Fact Sheet: CMS NHE Fact Sheet

Medicare Payment Advisory Commission, July 2026 Data Book: Health Care Spending and the Medicare Program

Third Wave of Ownership-Group Approvals; Commercial Rollout Expected Across 41 Additional Supermarket Locations

VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) — Beyond Oil Ltd. (TSX: BOIL) (OTCQB: BEOLF) (“Beyond Oil” or the “Company”), a food-tech innovation company dedicated to reducing health risks associated with fried food while improving food quality, lowering operational costs, minimizing waste and enhancing sustainability, announces that, further to its news releases dated March 30, 2026 and July 30, 2026, it has been approved to expand its commercial rollout into two additional ownership groups totaling 41 stores of a top-tier U.S. supermarket brand, ranked among North America’s top-30 food retailers by annual sales.¹

“The first two ownership groups validated the model. This third planned expansion is traction: a vote of confidence from two more ownership groups and 41 additional stores. It shows the potential scale of the U.S. opportunity. And it is only the start,” said Jonathan Or, CEO of Beyond Oil. “We built our U.S. commercial platform to win large multi-location customers and serve them directly. Food retail is now a major growth vertical for Beyond Oil, and we are positioned to keep converting across this network, with the potential to scale across hundreds of supermarkets in multiple states.”

This is the Company’s third expansion with ownership groups of the same supermarket brand. The first ownership group, announced March 30, 2026, followed a successful pilot with an initial commercial rollout across 13 locations. The second ownership group, announced July 30, 2026, added the rollout commitment for 14 high-volume supermarket locations, four of which were already operational at announcement. The two newly approved ownership groups are expected to add 41 high-volume locations.

Following the successful rollouts with the first and second ownership groups, Beyond Oil worked to fine-tune the program, ensure strong operator compliance and build an effective model for broader rollout. Those rollouts delivered strong operator satisfaction and measurable performance improvements, aligned with the broader supermarket brand’s priorities around food quality, worker safety and more sustainable kitchen operations. That operating model is now converting across the network.

The two additional ownership groups operate a combined 41 high-volume supermarket locations. Deployment across these locations is planned to proceed as the Company and the operators complete onboarding, training, initial location implementation, validate results, and then broader installation.

This milestone marks Beyond Oil’s continued scaling into the high-potential food retail vertical, where prepared-food programs represent a fast-growing segment characterized by very high frying volumes and strong recurring product usage. The Company believes this vertical represents a substantial expansion opportunity alongside its existing focus on quick-service restaurant chains and other foodservice operators.

About Beyond Oil Ltd.

We all love fried food. Let’s make it better. Not by changing what people love. By improving the system behind it. Beyond Oil Ltd. (TSX: BOIL, OTCQB: BEOLF) is a food-tech innovation company on a mission to help foodservice operators improve fried food across every dimension that matters: quality, health, consistency, safety, sustainability and profitability. We achieve these outcomes by improving the system behind every kitchen, the frying performance and oil management that determine what lands on the plate. The Company’s patented technology, cleared by the FDA and Health Canada, integrates into existing kitchen workflows to improve frying performance and oil management, helping operators deliver more consistent food, strengthen operational control and reduce oil waste. Beyond Oil’s solution serves restaurant chains, supermarkets, hotels, catering, institutions and industrial frying operations worldwide, turning frying into a measurable, repeatable and scalable brand standard. The result is a better frying standard, helping every fryer, every shift and every plate live up to the food people love. For more information, please visit: www.beyondoil.co.

Forward-Looking Statements and Information

This news release contains “forward-looking statements” within the meaning of the U.S. Securities Act of 1933, the U.S. Securities Exchange Act of 1934, “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of other relevant securities legislation, including applicable securities laws in Canada, which reflect Beyond Oil Ltd.’s current views with respect to, among other things, its operations and financial performance (collectively, “forward-looking statements”). Forward-looking statements include statements that are predictive in nature, depend upon or refer to future results, events or conditions, and include, but are not limited to, statements which reflect management’s current estimates, beliefs and assumptions and which are in turn based on our experience and perception of historical trends, current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. The estimates, beliefs and assumptions of Beyond Oil Ltd. are inherently subject to significant business, economic, competitive and other uncertainties and contingencies regarding future events and as such, are subject to change. Forward-looking statements are typically identified by words such as “expect”, “anticipate”, “believe”, “foresee”, “could”, “estimate”, “goal”, “intend”, “plan”, “seek”, “strive”, “will”, “may” and “should” and similar expressions. Although Beyond Oil Ltd., believes that such forward-looking statements are based upon reasonable estimates, beliefs and assumptions, certain factors, risks and uncertainties, which are described from time to time in our documents filed with the securities regulators in the USA and Canada, certain factors, not presently known to Beyond Oil Ltd., or that Beyond Oil Ltd., currently believes are not material, could cause actual results to differ materially from those contemplated or implied by forward-looking statements. Readers are urged to consider these risks, as well as other uncertainties, factors and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements, which are based only on information available to us as of the date of this news release. Except as required by law, Beyond Oil Ltd., undertakes no obligation to publicly update or revise any forward-looking statements, whether written or oral, that may be as a result of new information, future events or otherwise.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Company Contact:
Adi Olesker, VP of Investor Relations
Phone: +972-50-694-2517
adio@beyondoil.co

Investor Relations Contact:
Arx Investor Relations
North American Equities Desk
BOIL@arxhq.com

¹ Ranking source: Progressive Grocer, Julia Tabisz, “The PG 100: The 2026 Ranking of Top Food Retailers,” May 11, 2026. https://progressivegrocer.com/pg-100-2026-ranking-top-food-retailers

Translational research demonstrates that SIL204 utilizes native serum lipids to facilitate intracellular delivery and robust KRAS oncogene knockdown

Findings validate that physiological lipoprotein levels are sufficient for cellular entry without requiring artificial nanoparticles, supporting systemic administration in the Company’s Phase 2/3 clinical program

Grand Cayman, Cayman Islands, Sept. 28, 2026 (GLOBE NEWSWIRE) — Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced positive new findings from an ongoing translational study evaluating the cellular uptake and gene-silencing mechanism of its lead candidate, SIL204. The study, part of the Company’s translational research program supporting its Phase 2/3 clinical development, demonstrates that SIL204 effectively harnesses naturally occurring circulating lipoproteins to achieve cellular internalization and drive potent, dose-dependent knockdown of mutant KRAS oncogene expression in cancer cells.

Extending oligonucleotide delivery beyond the liver represents a major frontier in RNAi therapeutics.¹ The newly reported findings demonstrate that SIL204 is designed to utilize native lipid transport pathways to achieve intracellular delivery in tumor cells. In the study, conducted in a carrier-free, non-transfection assay without synthetic transfection reagents, human KRAS-driven cancer cells treated with SIL204 exhibited robust, dose-dependent gene silencing in the presence of standard physiological serum lipids. In contrast, depletion of serum lipids resulted in a statistically significant reduction in gene-knockdown efficiency (P < 0.001), confirming that circulating lipoproteins play a direct, functional role in mediating SIL204 cellular uptake and oncogenic silencing.²

Importantly, the addition of exogenous human low-density lipoprotein (LDL) did not alter gene-silencing potency compared to complete serum alone. This observation indicates that endogenous levels of circulating lipoproteins present under normal physiological conditions are already sufficient to support efficient cellular uptake and target knockdown, eliminating the need for external lipid supplementation or artificial carrier vehicles.

“These findings represent an essential mechanistic milestone in our translational characterization of SIL204,” said Dr. Mitchell Shirvan, Chief Scientific and Development Officer of Silexion Therapeutics. “One of the central design objectives of SIL204 was to engineer an oligonucleotide construct capable of entering target cancer cells efficiently while maintaining biological integrity. By demonstrating that SIL204 engages native lipoprotein pathways for cellular entry without requiring synthetic transfection reagents, we have demonstrated a fundamental biological mechanism that underpins its intracellular delivery. These results establish that standard physiological lipid levels are sufficient to enable potent target silencing, providing crucial mechanistic support as we advance our ongoing pharmacokinetic and biodistribution evaluations. Because the LDL receptor has been shown in vivo to be upregulated in cancer cells compared to healthy cells³, this represents an endogenous targeted delivery mechanism that is envisioned to improve the side effect profile in a clinically meaningful way.”

“Demonstrating this natural uptake mechanism reinforces our broader clinical development strategy and our Integrated Treatment Regimen for SIL204,” said Ilan Hadar, Chairman and Chief Executive Officer of Silexion Therapeutics. “While our Phase 2/3 clinical program in locally advanced pancreatic cancer targets the primary tumor, our vision has always encompassed systemic administration to address micro-metastases and distant disease spread. Confirming that SIL204 can leverage the body’s own lipid transport network for cellular entry provides a strong mechanistic foundation for systemic subcutaneous delivery. As we continue active site initiation and patient screening in our clinical program, these translational insights further validate the unique therapeutic potential of our next-generation RNAi platform.”

The findings emerge as Silexion continues translational characterization of SIL204 alongside clinical trial site initiation at Tel Aviv Sourasky Medical Center and regulatory clearances in Germany. Additional preclinical evaluations, including in vivo pharmacokinetic (PK), cellular uptake kinetics, and tissue biodistribution studies, are currently underway to further characterize the correlation between lipoprotein association, LDLR pathway engagement, systemic exposure, and anti-tumor activity in vivo.

About Silexion Therapeutics
Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers that have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The Company conducted a Phase 2a clinical trial in its first-generation product candidate, which showed a positive trend in comparison to the control of chemotherapy alone, and is now advancing its lead, second-generation, product candidate, SIL204, a small interfering RNA (siRNA), through Phase 2/3 clinical evaluation. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology and further developing its lead product candidate for locally advanced pancreatic cancer. For more information, please visit: https://silexion.com

Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication, including statements regarding the potential therapeutic benefits and future clinical development of SIL204, the Company’s ongoing and planned preclinical and clinical studies, including pharmacokinetic and biodistribution studies, and the potential future use of SIL204 for systemic administration, are forward-looking statements. These forward-looking statements are generally identified by terminology such as “may”, “should”, “could”, “might”, “plan”, “possible”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, or “potential”, or the negatives of these terms or variations of them or similar terminology. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to: (i) the inherent uncertainties associated with translational and preclinical research and drug development, including the risk that preliminary in vitro findings regarding cellular uptake, lipoprotein association, and gene silencing may not translate to in vivo pharmacokinetic models or clinical outcomes; (ii) Silexion’s ability to successfully complete additional preclinical and pharmacokinetic studies and initiate and conduct clinical trials, including the Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer; (iii) Silexion’s strategy, future operations, financial position, projected costs, prospects, and plans; (iv) the impact of the regulatory environment and compliance complexities, including site-level approvals, conditions, and clearances required prior to study commencement at clinical sites in Israel, Germany, and other jurisdictions; (v) expectations regarding future partnerships or other relationships with third parties; (vi) Silexion’s future capital requirements and sources and uses of cash, including its ability to obtain additional capital; (vii) Silexion’s ability to maintain its Nasdaq listing; and (viii) other risks and uncertainties set forth in the documents filed by the Company with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 17, 2026, and the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 14, 2026. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law.

Company Contact
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
info@silexion.com

Investor Relations Contact
Arx Investor Relations
North American Equities Desk
silexion@arxhq.com

____________________
¹ Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nature Reviews Drug Discovery 19, 673-694 (2020). DOI: https://doi.org/10.1038/s41573-020-0075-7
² Wolfrum C, Shi S, Jayaprakash KN, et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nature Biotechnology 25, 1149-1157 (2007). DOI: https://doi.org/10.1038/nbt1339
³ Guillaumond F, Bidaut G, Ouaissi M, et al. Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma. Proceedings of the National Academy of Sciences (PNAS) 112 (8), 2473-2478 (2015). DOI: https://doi.org/10.1073/pnas.1421601112

Manchester, 28 September 2026.- Virtualware (EPA: ALVIR), a European pioneer in 3D-driven industrial software listed on Euronext Growth Paris, has completed the acquisition of 100% of Virtalis Holding, the Manchester-based virtual reality and RT3D visualization software company.

The acquisition more than doubles the company’s scale, with pro forma revenue increasing from €4.32 million to €10 million based on projected 2026 results.

The combined group creates one of the largest European providers of immersive visualization and digital twin technology for industry, nuclear, critical infrastructure and defence.

“This acquisition marks a significant milestone for Virtualware, not only because of its scale, but also because it strengthens our product portfolio and expands our industrial customer base,” said Unai Extremo, CEO and founder of Virtualware.

Virtalis, founded in 2003 and headquartered in Manchester, specializes in virtual reality and RT3D visualization software. Its technology is used by BAE Systems, Blue Origin, Lam Research, Seaspan, Subsea 7, Vestas, Thales, Lockheed Martin and Ford.

The acquisition further strengthens Virtualware’s international footprint, rising its revenue generated outside Spain from 54% to 78%. The United Kingdom becomes the largest market, accounting for 37.7% of the proforma combined group’s aggregate revenue.

The acquisition follows Virtualware’s track record of inorganic growth. In October 2024 it acquired Swedish company Simumatik, a specialist in emulation and digital twin technology.

Shareholders approved the transaction at the Extraordinary General Meeting held in Basauri on 21 September 2026. The acquisition combines a fixed payment of 5 million euros on completion plus a variable component linked to Virtalis’s operating results in 2026 and 2027, funded through commercial debt.

LKS Corporate Finance served as Lead Financial Advisor to Virtualware on its acquisition of Virtalis, providing comprehensive financial advisory services, including valuation, transaction structuring, negotiations and deal execution and Geldars LLP as the legal advisor.

“We are proud to have supported Virtualware in the execution of a highly strategic acquisition that strengthens its international footprint and reinforces its leadership in industrial software.” Mariano Colmenar, Head of LKS Corporate Finance.

The acquisition was structured through a financial syndicate backed by Banco Bilbao Vizcaya Argentaria (BBVA), the Instituto Vasco de Finanzas (IVF, the Basque Government’s public financial entity), Cofides, and Elkargi.

—

Founded in 2004, Virtualware is one of the leading companies in enterprise software based on immersive and real-time 3D technologies for industrial and educational environments.

Virtualware is headquartered in Bilbao, Spain, with subsidiaries in the United Kingdom, Canada, the United States, and Sweden.

www.virtualwareco.com

Press and investors contacts

Aida Otaola: aotaola@virtualwareco.com

Investor Relations: ir@virtualwareco.com

Safe Harbor

This document is only provided for information purposes and does not constitute, nor should it be interpreted as, an offer to sell or exchange or acquire, or an invitation for offers to buy securities issued by any of the aforementioned companies. Any decision to buy or invest in securities in relation to a specific issue must be made solely and exclusively on the basis of the information set out in the pertinent prospectus filed by the company in relation to such specific issue. No one who becomes aware of the information contained in this report should regard it as definitive, because it is subject to changes and modifications.

This document contains or may contain forward looking statements regarding intentions, expectations or projections of Virtualware 2007, S.A. (“Virtualware” or the “Company”) or of its management on the date thereof, that refer to or incorporate various assumptions and projections, including projections about the future earnings of the business. The statements contained herein are based on our current projections, but the actual results may be substantially modified in the future by various risks and other factors that may cause the results or final decisions to differ from such intentions, projections or estimates. These factors include, without limitation, (1) the market situation, macroeconomic factors, regulatory, political or government guidelines, (2) domestic and international stock market movements, exchange rates and interest rates, (3) competitive pressures, (4) technological changes, (5) alterations in the financial situation, creditworthiness or solvency of our customers, debtors or counterparts. These factors could cause or result in actual events differing from the information and intentions stated, projected or forecast in this document or in other past or future documents. Virtualware does not undertake to publicly revise the contents of this or any other document, either if the events are not as described herein, or if such events lead to changes in the information contained in this document. This disclaimer needs to be taken into account by those persons which may take a decision over the base of this document or to elaborate or disseminate opinions based hereof.  This document may contain summarised information or information that has not been audited. This document is confidential and it cannot be revealed or disclosed to third parties different from the original recipients, even partially, without Virtualware’s prior consent.

Highlights 24 Months of Value Creation

VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) — Latin Metals Inc. (“Latin Metals” or the “Company“) (TSXV: LMS) (OTCQB: LMSQF) is pleased to announce that holders of the Company’s outstanding common share purchase warrants have exercised 100% of 12,500,000 million warrants at an exercise price of $0.15 per common share, providing $1,875,000 million in proceeds to the Company.

The warrant exercises provide Latin Metals with a meaningful addition to its treasury without undertaking a new equity financing and substantially reduces the Company’s near-term warrant overhang. The additional capital further strengthens Latin Metals’ financial position at a time when significant exploration expenditures across its portfolio are being funded at the project level by strategic partners under the Company’s prospect generator model.

Keith Henderson, President and CEO of Latin Metals, commented:

“The exercise of 100% of this warrant tranche represents a meaningful addition to Latin Metals’ treasury and demonstrates continued shareholder support for the Company. Importantly, this capital is being added at a time when significant exploration expenditures across our portfolio continue to be funded by our partners.

Over the past two years, Latin Metals has significantly expanded the scale of partner-funded exploration and investment across its portfolio, increasing estimated total investment under option agreements from approximately $16 million to $179 million.”

Following the exercise of the September 2026 warrants, the Company will have 151,565,650 common shares issued and outstanding and 12,095,454 warrants remaining outstanding at an exercise price of $0.20.

Latin Metals’ prospect generator strategy is designed to advance a diversified portfolio of copper, gold and silver exploration projects while securing well-funded partners to fund significant exploration expenditures at the project level. This model allows Latin Metals to maintain exposure to multiple potential discoveries while preserving capital and limiting shareholder-funded exploration expenditures.

Partner Investment Growth

Over the past 24 months, Latin Metals has substantially increased the amount of third-party capital and exploration commitments associated with its project portfolio. Between September 2024 and September 2026, total scheduled cash payments under option agreements increased from approximately $2.5 million to $21 million, while aggregate drilling meters under option agreements increased from 15,000 metres to 195,000 metres. Total potential investment under option agreements, including scheduled cash payments and estimated drill expenditures, increased from approximately $16 million to $179 million.

Latin Metals’ market capitalization has grown by approximately 400% over 24 months to September 2026 – from $7 million in September 2024 to $35 million in September 2026.

At the same time, Latin Metals’ expenditures have remained relatively stable on an annual basis.

Figure 1: Comparison of Partner Investment in September 2024, versus September 2026, illustrating significant growth in potential partner investment, and estimated percentage increases in various investment criteria.

This growth reflects the continued execution of Latin Metals’ prospect generator strategy, whereby the Company identifies and advances exploration opportunities before securing well-funded partners to assume a substantial portion of the high-cost exploration risk. The model is intended to expand shareholder exposure to multiple exploration programs while limiting the amount of Latin Metals’ own capital required to fund drilling and other high-cost exploration activities.

Regarding Figure 1 above, the figures presented for scheduled cash payments, drilling commitments and estimated investment under option agreements are based on the terms of the Company’s existing option agreements as at September 2026. To the extent that those figures relate to future periods, they constitute forward-looking information and assume, among other things, that the applicable option agreements remain in effect, the applicable option holders continue to advance those agreements through the relevant stages, scheduled payments are made and contractual drilling commitments are completed.

Actual results may differ materially. In particular, an option holder may elect not to proceed to a subsequent stage; an option agreement may be terminated, amended, surrendered or otherwise not completed; the timing or amount of scheduled payments may change; committed drilling may not be completed; actual drilling costs may differ materially from assumed costs; and the timing or scope of exploration programs may change. Accordingly, some or all of the cash payments, drilling commitments and estimated exploration investment illustrated in Figure 1 may not be received, completed or incurred, and the figures should not be interpreted as a forecast of amounts the Company expects to receive or expenditures that will necessarily be incurred.

Estimated investment attributable to drilling is based on assumed all-in drilling costs of approximately US$500 to US$700 per meter, depending on the project, based on costs observed at comparable projects, and actual costs may differ materially. Incoming cash payments include amounts paid or potentially payable directly to Latin Metals and, in certain cases, amounts paid or potentially payable under underlying option agreements. Total potential investment excludes discretionary top-up, buy-out and royalty buy-back payments. Latin Metals’ expenditures may vary depending on the number, timing, cost and scope of future acquisitions and exploration programs. Market capitalization figures are approximate point-in-time estimates and are not based on VWAP.

Correction to June 29, 2026 News Release

The Company wishes to correct its news release dated June 29, 2026 regarding the grant of 400,000 stock options. The news release incorrectly stated that the options were granted to certain directors, officers and consultants of the Company. The options were granted solely to consultants of the Company, and no options were granted to any directors or officers. All other terms of the option grant remain unchanged.

About Latin Metals

Latin Metals Inc. is a copper, gold and silver exploration company operating in Peru and Argentina under a prospect generator model, minimizing risk and dilution while maximizing discovery potential. The company secures option agreements with partners to fund exploration. This approach provides early-stage exposure to high-value mineral assets. Latin Metals is actively seeking new strategic partners to advance its portfolio.

Stay Connected

Follow Latin Metals on YouTube, X, Facebook, LinkedIn and Instagram to stay informed on our latest developments, exploration updates, and corporate news.

Upcoming Events

Latin Metals is pleased to announce its participation in several industry conferences, providing a platform to connect with investors, industry leaders, and potential partners:

• New Orleans Investment Conference – New Orleans, Louisiana, USA, October 28-31, 2026
• 121 London – London, UK, November 23-24, 2026

These events offer valuable opportunities to share Latin Metals’ exploration progress in Argentina and Peru, highlight the advantages of its low-dilution prospect generator model, and explore strategic investment and partnership opportunities across its gold, copper, and silver-focused portfolio.

Qualified Person

Eduardo Leon, QP, is the Company’s qualified person as defined by NI 43-101 and has reviewed the scientific and technical information that forms the basis for portions of this news release. He has approved the disclosure herein. Mr. Leon is not independent of the Company, as he is an employee of the Company and holds securities of the Company.

On Behalf of the Board of Directors of

LATIN METALS INC.

“Keith Henderson“

President & CEO

For further details on the Company, readers are referred to the Company’s website (www.latin-metals.com) and its Canadian regulatory filings on SEDAR+ at www.sedarplus.com.

For further information, please contact:

Keith Henderson
Suite 1920 – 1188 Georgia Street,
Vancouver, BC, V6E 4A2

Elyssia Patterson, VP Investor Relations
Email: elyssia@latin-metals.com
Phone: 778-683-4324

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Cautionary Note Regarding Forward-Looking Statements

This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities laws. All statements other than statements of historical fact may constitute forward-looking statements, including statements regarding anticipated exploration activities and results; the timing, scope and cost of exploration programs; the Company’s ability to acquire additional mineral properties and enter into option, earn-in or other agreements with exploration partners; scheduled or potential cash payments, drilling commitments and exploration expenditures under existing option agreements; estimated drilling costs and aggregate potential partner investment; the continuation and performance of option agreements; and the Company’s anticipated business plans and future activities.

Forward-looking statements are based on management’s current expectations, estimates, assumptions and projections as of the date of this news release. Material assumptions include, where applicable, that existing option agreements remain in effect, that option holders elect to continue to advance those agreements through the applicable stages, that scheduled payments and exploration commitments are made or completed, that exploration programs proceed substantially as presently contemplated, that assumed drilling costs are reasonable, that required permits and approvals are obtained when required, and that the Company and its exploration partners have access to sufficient financing and other resources to carry out their respective activities.

Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, activities or events to differ materially from those expressed or implied by such statements. These risks include, among others, the risk that an option holder may elect not to proceed to a subsequent stage of an option agreement; that an option agreement may be terminated, amended, surrendered or otherwise not completed; that the timing or amount of scheduled payments may change; that committed drilling or other exploration activities may not be completed; that actual drilling and exploration costs may differ materially from estimates; that the timing, scope or results of exploration programs may change; that permits or regulatory approvals may be delayed or not obtained; changes in commodity prices, financial markets and economic conditions; availability of financing; title and permitting risks; environmental and social risks; political and regulatory risks in the jurisdictions in which the Company operates; and the other risks described under “Risk Factors” in the Company’s most recently filed management’s discussion and analysis and other continuous disclosure documents available under the Company’s profile on SEDAR+.

Although the Company believes that the expectations and assumptions reflected in such forward-looking statements are reasonable, there can be no assurance that they will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements. Except as required by applicable securities laws, the Company undertakes no obligation to update or revise any forward-looking statements as a result of new information, future events or otherwise.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2f5c057d-0794-4df0-bd89-abe3224a22b0

NOT FOR DISTRIBUTION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW

CALGARY, Alberta, Sept. 28, 2026 (GLOBE NEWSWIRE) — Unless otherwise stated, all numbers in this press release are presented in Canadian dollars. Alaris Equity Partners Income Trust (“Alaris” or the “Trust“) (TSX: AD.UN) is pleased to announce the closing of the previously announced public offering (the “Offering“) of trust units of the Trust (“Units“) through a syndicate of underwriters (the “Underwriters“) led by CIBC Capital Markets, Acumen Capital Finance Partners Limited and National Bank of Canada Capital Markets and including Raymond James Ltd., Desjardins Capital Markets, RBC Capital Markets, ATB Capital Markets Corp., and Canaccord Genuity Corp., on a bought-deal basis. A total of 5,134,750 Units were issued in connection with the Offering at a price of $22.40 per Unit for aggregate gross proceeds of $115,018,400, which includes Units issued on the exercise in full of the over-allotment option granted to the Underwriters in connection with the Offering to purchase 669,750 Units.

The Trust intends to use the net proceeds of the Offering to partially repay outstanding indebtedness under its senior credit facility, which may be subsequently redrawn and used to fund future investments in new Partners (as defined below) and for general trust purposes.

ABOUT ALARIS

Alaris’ investment and investing activity refers to providing, through the wholly-owned subsidiaries of Alaris (the “Acquisition Entities“), structured equity to private companies (“Partners“) to meet their business and capital objectives, which includes management buyouts, dividend recapitalization, growth and acquisitions. Alaris achieves this by investing its unitholder capital, as well as debt, through the Acquisition Entities, in exchange for distributions, dividends or interest (collectively, “Distributions“) as well as capital appreciation on both preferred and common equity. The principal objective is to generate predictable cash flows for distribution payments to its unitholders while growing net book value through returns from capital appreciation. Distributions, other than common equity Distributions, from the Partners are adjusted annually based on the percentage change of a “top-line” financial performance measure such as gross margin or same store sales and rank in priority to common equity position.

This news release is not an offer of securities of Alaris for sale in the United States. The Units have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and the Units may not be offered or sold in the United States except pursuant to an applicable exemption from such registration. No public offering of securities is being made in the United States. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

FORWARD LOOKING STATEMENTS

This press release contains certain forward-looking information and statements within the meaning of applicable securities laws. The use of any of the words “expect”, “anticipate”, “continue”, “estimate”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends” and similar expressions are intended to identify forward-looking information or statements. In particular, but without limiting the foregoing, this press release contains forward-looking statements concerning the intended use of the net proceeds of the Offering. Although Alaris believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them because Alaris can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. The forward-looking statements contained in this press release are made as of the date hereof and Alaris undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

For further information please contact:

ir@alarisequity.com
P: (403) 260-1457
Alaris Equity Partners Income Trust
Suite 250, 333 24th Avenue S.W.
Calgary, Alberta T2S 3E6
www.alarisequitypartners.com

New U.S. patent expands intellectual property foundation for DARE-HPV, a potential first-in-category treatment targeting persistent high-risk HPV infection

DARE-HPV Phase 2 study underway with topline results expected in 2027; program supported by approximately $10 million in non-dilutive ARPA-H funding and a $2.0 million NIAID award

DARE-HPV is designed to address a major treatment gap for the millions of U.S. women who experience high-risk HPV infection each year, for which there is currently no FDA-approved pharmacologic treatment

SAN DIEGO, Sept. 28, 2026 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced the issuance of U.S. Patent No. 12,678,439, titled “Lopinavir and Ritonavir for the Treatment of Cervix Disorders,” which covers pharmaceutical compositions formulated for topical application comprising lopinavir and ritonavir for the treatment of HPV-related cervical pathologies.

The patent, issued by the United States Patent and Trademark Office on July 14, 2026, to Douglas Pharmaceuticals Limited, a licensor to Daré Bioscience, describes pharmaceutical compositions containing therapeutically effective amounts of lopinavir and ritonavir, including specific lopinavir-to-ritonavir weight ratios and formulations designed for topical administration. The patent includes claims directed to compositions for treating or inhibiting the development of early-stage neoplasias and for treating or preventing HPV-related cervical neoplasias. The patent is expected to provide protection into at least 2039.

“This patent adds another important layer to the foundation we are building around DARE-HPV at a particularly exciting point in the program’s development,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience. “Millions of women experience high-risk HPV infection each year in the United States, yet there is still no FDA-approved pharmacologic treatment to clear the infection. DARE-HPV is designed to change that paradigm with a localized, self-administered, non-surgical approach, and our Phase 2 study is now evaluating its potential to do exactly that. With clinical development underway, significant non-dilutive funding supporting the program, and an expanded intellectual property position, we believe DARE-HPV represents a compelling opportunity to address a significant unmet need in women’s health and, if successful and approved, potentially establishing the first FDA-approved pharmacologic treatment for HPV infection.”

The patent adds to the intellectual property landscape supporting the development of DARE-HPV, Daré Bioscience’s investigational proprietary fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert being developed as a potential treatment for persistent high-risk human papillomavirus (HPV) infection. Daré holds an exclusive U.S. license to the patent described above and the broader patent family related to DARE-HPV under its 2023 license agreement with Douglas Pharmaceuticals Limited.

DARE-HPV is currently being evaluated in a Phase 2 randomized, placebo-controlled, double-blind clinical study in approximately 100 women with confirmed persistent high-risk HPV infection (ClinicalTrials.gov ID: NCT07601074). The study is designed to evaluate the safety and antiviral activity of lower and higher doses of DARE-HPV compared with placebo over an up to 21-day course of daily treatment, with HPV clearance at three months post-treatment as the primary endpoint. Topline results are expected in 2027.

DARE-HPV is being developed as a non-surgical, localized, self-administered therapy designed to clear persistent high-risk HPV infection. There are currently no FDA-approved pharmacologic treatments for HPV infection. Daré Bioscience’s development of DARE-HPV is supported by approximately $10 million in non-dilutive funding from the Advanced Research Projects Agency for Health (ARPA-H) as Sprint for Women’s Health awardee, and a $2.0 million award granted by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (Award Number R44AI188623).

ABOUT DARE-HPV

DARE-HPV is an investigational, proprietary fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert being developed as a potential non-surgical, localized, self-administered treatment for persistent high-risk HPV infection. Lopinavir and ritonavir are protease inhibitors with established antiviral activity. HPV infection is the underlying cause of virtually all cervical cancer cases in the United States. An estimated six million women per year in the United States experience high-risk HPV infection, for which there are currently no FDA-approved pharmacologic treatments. If clinically successful and approved, DARE-HPV could be the first FDA-approved pharmacologic treatment for HPV infection.

ABOUT DARÉ BIOSCIENCE, INC.

Daré Bioscience (NASDAQ: DARE) is a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions. Every innovation Daré Bioscience advances is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, sexual health to fertility, vaginal health to infectious disease, Daré Bioscience is working to close critical gaps in care using science that serves her needs. For decades, women have been told to “wait it out” or “live with it,” while innovations that could improve their quality of life languish in the regulatory or funding pipeline. With growing awareness around menopause, sexual health, and vaginal health, the conversation is shifting. However, access to proven solutions is lagging. Daré Bioscience is working to change that. Learn more at darebioscience.com.

FORWARD-LOOKING STATEMENTS

Daré Bioscience cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “prepare,” “progress,” “seek,” “should,” “would,” “build” or the negative version of these words and similar expressions.

In this press release, forward-looking statements include, but are not limited to, statements relating to: DARE-HPV’s potential as a safe and effective treatment for clearance of high-risk HPV infection; DARE-HPV’s potential to be a first-in-category treatment targeting persistent high-risk HPV infection and to be the first FDA-approved pharmacologic treatment for high-risk HPV infection; the conduct and completion of the Phase 2 clinical study of DARE-HPV and the timing of topline data from the study; the anticipated benefits of DARE-HPV, including its potential to reduce the incidence of cervical cancer in the U.S.; the potential for DARE-HPV to redefine the treatment paradigm in cervical disease prevention; the expected duration of patent protection into at least 2039; Daré Bioscience’s expectation of receipt of additional funding under its ARPA-H award and NIAID award; and the potential market opportunity for DARE-HPV, if approved. As used in this press release, “first-in-category” is a forward-looking statement relating to the potential of a product candidate to represent a new category of product if it were to receive marketing approval for the indication for which it is being developed because Daré Bioscience believes it would address a need in women’s health that is not being met by existing FDA-approved products.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Daré Bioscience’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: failure or delay in conducting or completing clinical trials and the inherent uncertainty of outcomes of clinical trials; the risk that positive findings in early clinical and/or nonclinical studies of a product candidate may not be predictive of success in subsequent clinical and/or nonclinical studies of that candidate; Daré Bioscience’s ability to develop, obtain FDA or foreign regulatory approval for, and commercialize its product candidates and to do so on communicated timelines; the risk that Daré Bioscience’s product candidates may fail to demonstrate acceptable safety and tolerability or sufficient efficacy in clinical trials; Daré Bioscience’s ability to design and conduct successful clinical trials, to enroll a sufficient number of patients, to meet established clinical endpoints, to avoid undesirable side effects and other safety concerns, and to demonstrate sufficient safety and efficacy of its product candidates; Daré Bioscience’s dependence on third parties to conduct clinical trials and manufacture and supply clinical trial material and commercial product; the potential that a product candidate in clinical development may never advance into or through a pivotal clinical study or obtain FDA or foreign regulatory approval; the risk that the FDA, other regulatory authorities, members of the scientific or medical communities or investors may not accept or agree with Daré Bioscience’s interpretation of or conclusions regarding data from clinical studies of its product candidates; the risk that development of a product candidate requires more clinical or nonclinical studies than Daré Bioscience anticipates, or that the duration of a study or number of study subjects must be significantly greater than anticipated; Daré Bioscience’s ability to achieve the milestones required for it to receive additional payments under its ARPA-H award and NIAID award; Daré Bioscience’s dependence on grants and other financial awards from governmental entities and the risk that funding may be reduced, delayed, or terminated; Daré Bioscience’s ability to raise additional capital when and as needed to execute its business strategy and continue as a going concern; Daré Bioscience’s ability to maintain compliance with Nasdaq’s continued listing requirements and continue to have its common stock listed on The Nasdaq Capital Market; the effects of macroeconomic conditions, geopolitical events, and major changes and disruptions in U.S. government policies and operations on Daré Bioscience’s ability to raise additional capital or on Daré Bioscience’s operations, financial results and condition, and ability to achieve current plans and objectives; the risk that the intellectual property landscape supporting DARE-HPV, including the newly issued patent and the licensed patent family, may not provide the expected scope or duration of protection, and the risk that patent protection may not extend into 2039 as currently expected; the risk that the current regulatory pathway known as the FDA’s 505(b)(2) pathway for drug product approval in the U.S. is not available for a product candidate as Daré Bioscience anticipates; the risk that developments by competitors make Daré Bioscience’s product or product candidates less competitive or obsolete; difficulties establishing and sustaining relationships with development and/or commercial collaborators; failure of Daré Bioscience’s products or product candidates, if approved, to gain market acceptance or obtain adequate coverage, pricing and reimbursement from third-party payors; Daré Bioscience’s ability to retain its licensed rights to develop and commercialize a product or product candidate; Daré Bioscience’s ability to satisfy the monetary obligations and other requirements in connection with its exclusive, in-license agreements covering the critical patents and related intellectual property related to its products and product candidates; Daré Bioscience’s ability to adequately protect or enforce its, or its licensor’s, intellectual property rights; the lack of patent protection for the active ingredients in certain of Daré Bioscience’s product candidates, which could expose its products to competition from other formulations using the same active ingredients; product liability claims; governmental investigations or actions relating to Daré Bioscience’s products or product candidates or the business activities of Daré Bioscience, its commercial collaborators or other third parties on which Daré Bioscience relies; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; and cybersecurity incidents or similar events that compromise Daré Bioscience’s technology systems and/or significantly disrupt Daré Bioscience’s business or those of third parties on which Daré Bioscience relies.

Daré Bioscience’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Daré Bioscience’s risks and uncertainties, you are encouraged to review its documents filed with the U.S. Securities and Exchange Commission (SEC), including Daré Bioscience’s recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Daré Bioscience undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Contact:
Daré Bioscience Investor Relations
innovations@darebioscience.com 
Source: Daré Bioscience, Inc.

Borregaard has today entered into three bilateral multicurrency revolving credit facility agreements with Danske Bank, DNB Bank ASA, and Skandinaviska Enskilda Banken, respectively. The facilities, which are linked to sustainability targets, amount in total to NOK 1,500 million, with each bank providing NOK 500 million.

The margin under the respective facilities can be adjusted based on Borregaard’s progress on three parameters: (i) the Group’s target of reducing greenhouse gas emissions (Scope 1 and 2), (ii) reduction of the Group’s total recordable injuries and (iii) reduced emissions of organic compounds to the Glomma river.

The facilities have tenors of five years with two one-year extension options. The new facilities are for general corporate purposes and replace the NOK 1,500 million revolving credit facilities with maturity in 2027.

Skandinaviska Enskilda Banken acted as documentation coordinator for the facilities.

Borregaard ASA,
Sarpsborg, 28 September 2026

Contact:
Group Treasurer and IR, Magnus Hammerstad, +47 959 04 640

This information is subject to the disclosure requirements pursuant to Section 5 -12 of the Norwegian Securities Trading Act and requirements under the EU Market Abuse Regulation.

Enters into a non-binding term sheet which will potentially provide control over two data center development projects in Warsaw and Wroclaw, Poland, with planned capacity of up to 270 MW

NESS ZIONA, Israel, Sept. 28, 2026 (GLOBE NEWSWIRE) — Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“Foresight” or the “Company”), an innovator in 3D perception systems, announced today that it has entered into a non-binding term sheet for the proposed acquisition of a 50.01% controlling interest in a company advancing data center development projects in Poland (the “Data Centers Company”).

The Data Centers Company is expected to hold a 66.67% interest in each of two Polish project companies developing data centers in Warsaw and Wroclaw, two of the biggest and growing cities in Poland. The Warsaw project has a planned power capacity of 130 MW, while the Wroclaw project has a planned capacity of up to 140 MW, representing combined planned capacity of up to 270 MW.

The remaining 33.33% interest in both projects will be held by Polish development entrepreneurs who are engineering experts leading national grid connection processes, techno-economic analysis and regulatory matters and lead the securing of grid connection terms for projects totaling several gigawatts.

The Warsaw project, located in Ożarów, Poland, includes approximately 3.2 hectares of secured land, with an additional 2.2-hectare option. A grid connection application has been submitted, with final permit currently expected by the end of 2027. The Wroclaw project encompasses approximately 10 hectares, with its feasibility study completed and land currently under negotiation.

According to the data produced by the European Data Centre Association , Poland’s colocation capacity is forecast to increase from approximately 29 MW in 2026 to 511 MW by 2031, underscoring the country’s position as a growing data center market in the Central and Eastern Europe.

Haim Siboni, Chief Executive Officer of Foresight, said, “As we previously announced, Foresight has been evaluating opportunities to expand into new technology markets and identify additional areas for growth beyond our existing activities, including data centers. The proposed transaction is a natural extension of this strategy, providing Foresight with an opportunity to establish a controlling interest in a platform advancing two data center projects in Poland. At the same time, we continue to advance our proprietary technologies and expand their applications, including our recently announced development of full autonomous driving solutions for Unmanned Ground and Aerial Vehicles.”

The purchase price for the 50.01% interest in the Data Centers Company will be determined based on an independent valuation to be prepared by a mutually agreed independent valuation firm prior to execution of definitive agreements. The consideration would be financed in full through a seller loan.

At closing, Foresight expects to also contribute an amount currently estimated at approximately $1 million, representing its pro rata share of the Data Centers Company’s outstanding shareholder loans, and would commit to provide additional shareholder loans of up to $2.5 million to advance the two projects. To fund these obligations, the Data Centers Company current shareholders, or anyone on their behalf, shall provide Foresight with a convertible loan facility, from time to time, of up to US$3,500,000, all subject to an agreed budget, business plan and projects milestones, with terms to be agreed upon a separate agreement.

The proposed transaction remains subject to the completion of Foresight’s due diligence, an independent valuation, agreement on definitive transaction documents and transaction structure, and receipt of required corporate, regulatory, stock exchange, governmental, financing, and third-party approvals.

Eli Yoresh, the Company’s Chief Financial Officer, owns a 10% stake in the Data Centers Company.

About Foresight

Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) is a technology company developing advanced three-dimensional (3D) perception systems and cellular-based applications. Through its wholly owned subsidiaries, Foresight Automotive Ltd., Foresight Changzhou Automotive Ltd., and Eye-Net Mobile Ltd., Foresight develops both “in-line-of-sight” vision systems and “beyond-line-of-sight” accident-prevention solutions.

Foresight’s 3D perception systems include modules of automatic calibration and dense 3D point cloud that can be applied to different markets such as automotive, defense, autonomous driving, agriculture, heavy industrial equipment, and unmanned aerial vehicles (UAVs).

Eye-Net Mobile develops next-generation vehicle-to-everything collision prevention solutions and smart automotive systems to enhance road safety and situational awareness for all road users in urban mobility environments. By leveraging cutting-edge artificial intelligence technology, advanced analytics, and existing cellular networks, Eye-Net’s innovative solution suite delivers real-time pre-collision alerts to all road users via smartphones and other smart devices within vehicles.

For more information about Foresight and its wholly owned subsidiary, Foresight Automotive, visit www.foresightauto.com, follow @ForesightAuto1 on X, or join Foresight Automotive on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, Foresight is using forward-looking statements in this press release when it discusses the likelihood of success of data center development in Poland, possible growth in the European energy market, the likelihood of energy production by the potential data centers, entry into definitive agreements and future cooperation between the parties to the nonbinding term sheet and that the proposed transaction remains subject to the completion of Foresight’s due diligence, an independent valuation, agreement on definitive transaction documents and transaction structure, and receipt of required corporate, regulatory, stock exchange, governmental, financing, and third-party approvals. Because such statements deal with future events and are based on Foresight’s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of Foresight could differ materially from those described in or implied by the statements in this press release.

The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Foresight’s annual report on Form 20-F for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 25, 2026, and in any subsequent filings with the SEC. Except as otherwise required by law, Foresight undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Foresight is not responsible for the content of third party websites.

Investor Relations Contact:
Miri Segal-Scharia
CEO
MS-IR LLC
msegal@ms-ir.com